Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase
暂无分享,去创建一个
Lei Yu | L. Yao | J. Cen | Hong-jie Shen | Depei Wu | Xiaowen Tang | Xiaowen Tang | Depei Wu | Jia Yin | P. Liang | Zheng Li | H. Dai | Q. Cui | L. Kang | Lei Yu | Si-Ning Liu | Zheng Li | Z. Ding | M. Zhu | Qin-fen Ma | W. Cui | Li Yao | M. Cai | Qinfen Ma | Jia Yin | Sining Liu | Hongjie Shen | Mingqing Zhu | Sining Liu | Hongjie Shen | Liqing Kang | Hai-ping Dai
[1] A. E. Eşkazan,et al. Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review , 2022, Expert review of hematology.
[2] I. Haznedaroglu,et al. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. , 2021, European review for medical and pharmacological sciences.
[3] M. Tiribelli,et al. Asciminib as a new option in the treatment of chronic myeloid leukemia. , 2021, Future oncology.
[4] Depei Wu,et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation , 2020, Journal of Hematology & Oncology.
[5] Jiang F Zhong,et al. Recent advances in CAR-T cell engineering , 2020, Journal of Hematology & Oncology.
[6] Blastic Phase , 2020, Definitions.
[7] S. Soverini,et al. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update , 2019, International journal of molecular sciences.
[8] M. Konopleva,et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients , 2017, Cancer.
[9] Genee Y. Lee,et al. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. , 2017, Blood.
[10] Bie M. P. Verbist,et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. , 2016, Blood.
[11] J. Szer,et al. All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand , 2016, Bone Marrow Transplantation.
[12] P. Parren,et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma , 2015, Haematologica.
[13] Hao Jiang,et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis , 2014, Bone Marrow Transplantation.
[14] Xiuli Wang,et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. , 2013, Blood.
[15] Yan Zheng,et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. , 2013, Current opinion in immunology.
[16] R. Hehlmann. How I treat CML blast crisis. , 2012, Blood.
[17] I. Bernstein,et al. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. , 2012, Blood.
[18] R. Larson,et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase , 2012, Leukemia.
[19] A. Hamilton,et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. , 2012, Blood.
[20] H. Dombret,et al. Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study , 2010, Cancer.
[21] R. Zini,et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. , 2008, Blood.
[22] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[23] H. Kantarjian,et al. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy , 2002, Cancer.
[24] D. Marin,et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. , 2002, Blood.
[25] M. Baccarani,et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia , 2016, Leukemia.
[26] Teresa Foo,et al. : SYSTEMATIC LITERATURE REVIEW , 2004 .
[27] M. Konopleva,et al. CD38 in hematopoietic malignancies. , 2000, Chemical immunology.
[28] K. Johnson. An Update. , 1984, Journal of food protection.